Risk of glaucoma among patients using tadalafil for lower urinary tract symptoms: a multinational cohort study.

The cohort included 36 927 tadalafil users and 36 927 matched non-PDE5i users.

Elevated risks were observed for ocular hypertension (HR 1.32; 95% CI 1.06 to 1.65), primary open-angle glaucoma (HR 1.33; 95% CI 1.05 to 1.67) and initiation of glaucoma treatment (HR 1.33; 95% CI 1.20 to 1.47).

No significant associations were found for low-tension or primary angle-closure glaucoma.

Tadalafil users had a higher 5-year cumulative incidence than non-users (3.93% vs 3.16%; p<0.001), with consistent risk in men >50 years, white population and across comorbidities, remaining robust to 1-, 3- and 6-month lag times.